Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 3 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 47 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
20 other companies have their registered office at the same address; threshold 10.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
Raya Therapeutic from Leuven, company number BE1003128171, closed financial year 2025 with a result of € -4,003 after tax. For that financial year Raya Therapeutic recorded a gross margin of € -3,717 and equity of € -5,962. Compared with financial year 2024, the result moved from € -7,040 to € -4,003. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on April 29, 2026.
€ -5,962
▼ € 4,003 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -4,003
▲ 43 % less loss than in 2024
Profit after tax over the fiscal year.
€ 5,303
▲ 7% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -11,043.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 1,477
▼ 83% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | - | € -6,933 | € -3,717 | ▲ € 3,216 |
| Profit after taxes | € 0 | € -7,040 | € -4,003 | ▲ € 3,037 |
| Equity | € 5,081 | € -1,959 | € -5,962 | ▼ € 4,003 |
| Total debts | € 0 | € 8,636 | € 11,292 | ▲ 31% |
| Cash | € 5,081 | € 4,970 | € 5,303 | ▲ 7% |
| Retained profit | € 0 | € -7,040 | € -11,043 | ▼ € 4,003 |
| Balance sheet total | € 5,081 | € 6,676 | € 5,330 | ▼ 20% |
Key figures of Raya Therapeutic, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.
What happened to Raya Therapeutic?
What happened at Raya Therapeutic in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 4,003. Source: NBB ↗
- New establishment in Leuven. KBO
- Start of the company according to the CBE. KBO
In short
From € 0 profit in 2023 to € 4,003 loss in 2025.
A new publication or filing at Raya Therapeutic? We notify you, reason included.
Follow Raya TherapeuticDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Raya Therapeutic is Anjan Aralihalli.
Directors
According to the 2025 annual accounts
Anjan Aralihalli
Director
Establishments
Establishment units
Physical locations of this company
Gaston Geenslaan 1
3001 Leuven
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.
All companies at this address →reMYND
€ -217,249 gross margin · 2025
DName-iT
€ -71,430 gross margin · 2025
miDiagnostics
€ 24,934 revenue · 2025
ALIGOS BELGIUM
€ 3.2 million gross margin · 2025
Pledge Therapeutics
€ -97,474 gross margin · 2024
+15 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1003.128.171
- VAT number
- BE 1003.128.171
- Registered office
- Gaston Geenslaan 1, 3001 Leuven
- Names & denominations
- Raya Therapeutic
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 7 December 2023
- Peppol
- Not registered
- Activities · NACE
Vervaardiging van farmaceutische grondstoffen
Speur- en ontwikkelingswerk op biotechnologisch gebied